CRESCENT BIOPHARMA, INC. Earnings Per Share Disclosure
| Twelve Months Ended December 31, 2025 | ||||||||||||||
| Loss Allocation | Weighted Average Shares Outstanding | Loss Per Share, Basic and Diluted | ||||||||||||
| Ordinary Shares | $ | (133,446) | 10,413,649 | $ | (12.81) | |||||||||
Company Series A Preferred Shares (1) | (20,496) | 1,599 | $ | (12,818.01) | ||||||||||
| Net loss | $ | (153,942) | ||||||||||||
| Period from September 19, 2024 (Inception) Through December 31, 2024 | ||||||||||||||
| Loss Allocation | Weighted Average Shares Outstanding | Loss Per Share, Basic and Diluted | ||||||||||||
| Common Stock | $ | (17,867) | 767,580 | $ | (23.28) | |||||||||
| Net loss | $ | (17,867) | ||||||||||||
| Twelve Months Ended December 31, 2025 | Period from September 19, 2024 (Inception) Through December 31, 2024 | ||||||||||
| Convertible preferred stock (as converted to common stock) | — | 2,890,000 | |||||||||
| Outstanding unvested restricted stock units | 741,454 | — | |||||||||
| Outstanding unvested restricted stock awards | 82,129 | 246,753 | |||||||||
| Outstanding and issued common stock options | 6,186,318 | 1,082,893 | |||||||||
| Total | 7,009,901 | 4,219,646 | |||||||||
Want the next CRESCENT BIOPHARMA, INC. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment CRESCENT BIOPHARMA, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.